This trial is unknown!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Acute Heart Failure
and you are
over 18
years old
Phase
3
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

Patients being hospitalized for acute heart failure and already receiving standard therapy will be randomized to receive either tolvaptan or placebo, based on the level of copeptin measured in their bloodstream. Patients with high copeptin levels will be able to participate in the trial, patients with low levels will be excluded. Patients being admitted to the observation unit for acute heart failure and already receiving standard therapy will be randomized to receive either tolvaptan or placebo without consideration of the copeptin level. The hypothesis is that patients receiving tolvaptan will have better improvement of shortness of breath than those receiving placebo, within 9 hours of drug administration.

Provided treatments

  • Drug: Tolvaptan
  • Drug: placebo
Tris trial is registered with FDA with number: NCT01733134. The sponsor of the trial is Maisel, Alan, M.D. and it is looking for 350 volunteers for the current phase.
Official trial title:
Acute Heart Failure With High Copeptin Levels Treated With Tolvaptan Targets Increased AVP Activation for Treatment Efficacy